nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP3A4—Imiquimod—skin cancer	0.104	0.233	CbGbCtD
Lisuride—CYP3A4—Temozolomide—skin cancer	0.104	0.233	CbGbCtD
Lisuride—CYP2D6—Vemurafenib—skin cancer	0.09	0.201	CbGbCtD
Lisuride—CYP3A4—Vismodegib—skin cancer	0.0724	0.162	CbGbCtD
Lisuride—CYP3A4—Vemurafenib—skin cancer	0.0572	0.128	CbGbCtD
Lisuride—DRD5—eyelid—skin cancer	0.0436	0.261	CbGeAlD
Lisuride—CYP3A4—Docetaxel—skin cancer	0.0196	0.0438	CbGbCtD
Lisuride—Pulmonary fibrosis—Bleomycin—skin cancer	0.00924	0.0318	CcSEcCtD
Lisuride—DRD1—nerve—skin cancer	0.00888	0.0532	CbGeAlD
Lisuride—Pulmonary fibrosis—Temozolomide—skin cancer	0.0078	0.0268	CcSEcCtD
Lisuride—Dehydration—Vismodegib—skin cancer	0.00733	0.0252	CcSEcCtD
Lisuride—Pericarditis—Fluorouracil—skin cancer	0.00731	0.0251	CcSEcCtD
Lisuride—Weight decreased—Vismodegib—skin cancer	0.00617	0.0212	CcSEcCtD
Lisuride—HTR2A—hindlimb—skin cancer	0.00569	0.0341	CbGeAlD
Lisuride—HTR1B—blood vessel—skin cancer	0.00565	0.0338	CbGeAlD
Lisuride—Pericardial effusion—Docetaxel—skin cancer	0.00556	0.0191	CcSEcCtD
Lisuride—HTR1D—blood vessel—skin cancer	0.00547	0.0328	CbGeAlD
Lisuride—DRD2—nerve—skin cancer	0.00525	0.0314	CbGeAlD
Lisuride—Pulmonary fibrosis—Docetaxel—skin cancer	0.00519	0.0178	CcSEcCtD
Lisuride—HTR2A—appendage—skin cancer	0.00488	0.0292	CbGeAlD
Lisuride—Malnutrition—Vismodegib—skin cancer	0.00475	0.0163	CcSEcCtD
Lisuride—Aggression—Bleomycin—skin cancer	0.00463	0.0159	CcSEcCtD
Lisuride—Weight decreased—Vemurafenib—skin cancer	0.00381	0.0131	CcSEcCtD
Lisuride—Nervous system disorder—Vismodegib—skin cancer	0.0038	0.0131	CcSEcCtD
Lisuride—ADRA1D—epithelium—skin cancer	0.00356	0.0213	CbGeAlD
Lisuride—HTR2A—nerve—skin cancer	0.00346	0.0207	CbGeAlD
Lisuride—DRD5—lymphoid tissue—skin cancer	0.00342	0.0205	CbGeAlD
Lisuride—Decreased appetite—Vismodegib—skin cancer	0.00337	0.0116	CcSEcCtD
Lisuride—Gastrointestinal disorder—Vismodegib—skin cancer	0.00335	0.0115	CcSEcCtD
Lisuride—Fatigue—Vismodegib—skin cancer	0.00334	0.0115	CcSEcCtD
Lisuride—Oedema peripheral—Vemurafenib—skin cancer	0.00332	0.0114	CcSEcCtD
Lisuride—Constipation—Vismodegib—skin cancer	0.00331	0.0114	CcSEcCtD
Lisuride—DRD5—female reproductive system—skin cancer	0.0033	0.0198	CbGeAlD
Lisuride—Disorientation—Bleomycin—skin cancer	0.0033	0.0113	CcSEcCtD
Lisuride—Cardiac disorder—Vemurafenib—skin cancer	0.00313	0.0108	CcSEcCtD
Lisuride—Angiopathy—Vemurafenib—skin cancer	0.00306	0.0105	CcSEcCtD
Lisuride—Mediastinal disorder—Vemurafenib—skin cancer	0.00304	0.0104	CcSEcCtD
Lisuride—Pleural effusion—Docetaxel—skin cancer	0.00298	0.0102	CcSEcCtD
Lisuride—HTR2A—endothelium—skin cancer	0.00295	0.0176	CbGeAlD
Lisuride—DRD3—head—skin cancer	0.00294	0.0176	CbGeAlD
Lisuride—Malnutrition—Vemurafenib—skin cancer	0.00293	0.0101	CcSEcCtD
Lisuride—ADRA2C—nipple—skin cancer	0.0029	0.0173	CbGeAlD
Lisuride—HTR1D—connective tissue—skin cancer	0.0028	0.0168	CbGeAlD
Lisuride—Asthenia—Vismodegib—skin cancer	0.00278	0.00956	CcSEcCtD
Lisuride—DRD5—head—skin cancer	0.00276	0.0165	CbGeAlD
Lisuride—ADRB1—connective tissue—skin cancer	0.00273	0.0163	CbGeAlD
Lisuride—HTR2A—blood vessel—skin cancer	0.00272	0.0163	CbGeAlD
Lisuride—ADRA1D—female reproductive system—skin cancer	0.00265	0.0158	CbGeAlD
Lisuride—Angiopathy—Imiquimod—skin cancer	0.00261	0.00896	CcSEcCtD
Lisuride—Immune system disorder—Imiquimod—skin cancer	0.0026	0.00892	CcSEcCtD
Lisuride—Mediastinal disorder—Imiquimod—skin cancer	0.00259	0.0089	CcSEcCtD
Lisuride—Disorientation—Fluorouracil—skin cancer	0.00256	0.00882	CcSEcCtD
Lisuride—Cough—Vemurafenib—skin cancer	0.00256	0.0088	CcSEcCtD
Lisuride—Mental disorder—Imiquimod—skin cancer	0.00252	0.00866	CcSEcCtD
Lisuride—Malnutrition—Imiquimod—skin cancer	0.0025	0.0086	CcSEcCtD
Lisuride—Vomiting—Vismodegib—skin cancer	0.00246	0.00847	CcSEcCtD
Lisuride—Infection—Vemurafenib—skin cancer	0.00238	0.00818	CcSEcCtD
Lisuride—HTR2B—skin of body—skin cancer	0.00236	0.0141	CbGeAlD
Lisuride—Nervous system disorder—Vemurafenib—skin cancer	0.00235	0.00807	CcSEcCtD
Lisuride—Dehydration—Temozolomide—skin cancer	0.00232	0.00796	CcSEcCtD
Lisuride—ADRA2A—nipple—skin cancer	0.00231	0.0138	CbGeAlD
Lisuride—Weight decreased—Bleomycin—skin cancer	0.00231	0.00793	CcSEcCtD
Lisuride—Blood pressure increased—Docetaxel—skin cancer	0.00228	0.00784	CcSEcCtD
Lisuride—ADRA1B—head—skin cancer	0.00226	0.0135	CbGeAlD
Lisuride—Syncope—Imiquimod—skin cancer	0.00224	0.00771	CcSEcCtD
Lisuride—Palpitations—Imiquimod—skin cancer	0.00221	0.0076	CcSEcCtD
Lisuride—ADRA1D—head—skin cancer	0.00221	0.0132	CbGeAlD
Lisuride—Cough—Imiquimod—skin cancer	0.00218	0.00751	CcSEcCtD
Lisuride—Anxiety—Imiquimod—skin cancer	0.00212	0.0073	CcSEcCtD
Lisuride—DRD1—head—skin cancer	0.00211	0.0126	CbGeAlD
Lisuride—Dry mouth—Imiquimod—skin cancer	0.00208	0.00716	CcSEcCtD
Lisuride—Decreased appetite—Vemurafenib—skin cancer	0.00208	0.00716	CcSEcCtD
Lisuride—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00207	0.00711	CcSEcCtD
Lisuride—Fatigue—Vemurafenib—skin cancer	0.00206	0.0071	CcSEcCtD
Lisuride—Constipation—Vemurafenib—skin cancer	0.00205	0.00704	CcSEcCtD
Lisuride—HTR1B—female reproductive system—skin cancer	0.00204	0.0122	CbGeAlD
Lisuride—Infection—Imiquimod—skin cancer	0.00203	0.00697	CcSEcCtD
Lisuride—Nervous system disorder—Imiquimod—skin cancer	0.002	0.00688	CcSEcCtD
Lisuride—Tachycardia—Imiquimod—skin cancer	0.00199	0.00685	CcSEcCtD
Lisuride—HTR1D—female reproductive system—skin cancer	0.00198	0.0118	CbGeAlD
Lisuride—Hyperhidrosis—Imiquimod—skin cancer	0.00197	0.00679	CcSEcCtD
Lisuride—HTR2C—female reproductive system—skin cancer	0.00196	0.0117	CbGeAlD
Lisuride—Weight increased—Temozolomide—skin cancer	0.00196	0.00673	CcSEcCtD
Lisuride—Weight decreased—Temozolomide—skin cancer	0.00195	0.00669	CcSEcCtD
Lisuride—Anorexia—Imiquimod—skin cancer	0.00195	0.00669	CcSEcCtD
Lisuride—HTR2A—neck—skin cancer	0.00194	0.0116	CbGeAlD
Lisuride—ADRB1—female reproductive system—skin cancer	0.00192	0.0115	CbGeAlD
Lisuride—Insomnia—Imiquimod—skin cancer	0.00185	0.00635	CcSEcCtD
Lisuride—HTR2B—female reproductive system—skin cancer	0.00184	0.011	CbGeAlD
Lisuride—Dyspnoea—Imiquimod—skin cancer	0.00182	0.00626	CcSEcCtD
Lisuride—Somnolence—Imiquimod—skin cancer	0.00182	0.00624	CcSEcCtD
Lisuride—Decreased appetite—Imiquimod—skin cancer	0.00177	0.0061	CcSEcCtD
Lisuride—Gastrointestinal disorder—Imiquimod—skin cancer	0.00176	0.00606	CcSEcCtD
Lisuride—Fatigue—Imiquimod—skin cancer	0.00176	0.00605	CcSEcCtD
Lisuride—Asthenia—Vemurafenib—skin cancer	0.00172	0.00591	CcSEcCtD
Lisuride—Hallucination—Temozolomide—skin cancer	0.00171	0.00589	CcSEcCtD
Lisuride—HTR1B—head—skin cancer	0.00171	0.0102	CbGeAlD
Lisuride—Oedema peripheral—Temozolomide—skin cancer	0.0017	0.00583	CcSEcCtD
Lisuride—ADRA2C—mammalian vulva—skin cancer	0.00169	0.0101	CbGeAlD
Lisuride—Feeling abnormal—Imiquimod—skin cancer	0.00168	0.00578	CcSEcCtD
Lisuride—HTR1D—head—skin cancer	0.00165	0.0099	CbGeAlD
Lisuride—ADRA2A—connective tissue—skin cancer	0.00164	0.00981	CbGeAlD
Lisuride—HTR2C—head—skin cancer	0.00164	0.0098	CbGeAlD
Lisuride—ADRB1—head—skin cancer	0.00161	0.00962	CbGeAlD
Lisuride—Cardiac disorder—Temozolomide—skin cancer	0.0016	0.0055	CcSEcCtD
Lisuride—Dizziness—Vemurafenib—skin cancer	0.00158	0.00544	CcSEcCtD
Lisuride—Angiopathy—Temozolomide—skin cancer	0.00156	0.00537	CcSEcCtD
Lisuride—Immune system disorder—Temozolomide—skin cancer	0.00156	0.00535	CcSEcCtD
Lisuride—Mediastinal disorder—Temozolomide—skin cancer	0.00155	0.00534	CcSEcCtD
Lisuride—Cough—Bleomycin—skin cancer	0.00155	0.00533	CcSEcCtD
Lisuride—Dehydration—Docetaxel—skin cancer	0.00154	0.00529	CcSEcCtD
Lisuride—HTR2B—head—skin cancer	0.00154	0.00921	CbGeAlD
Lisuride—Vomiting—Vemurafenib—skin cancer	0.00152	0.00523	CcSEcCtD
Lisuride—Orthostatic hypotension—Docetaxel—skin cancer	0.00151	0.0052	CcSEcCtD
Lisuride—Mental disorder—Temozolomide—skin cancer	0.00151	0.00519	CcSEcCtD
Lisuride—Headache—Vemurafenib—skin cancer	0.0015	0.00516	CcSEcCtD
Lisuride—Malnutrition—Temozolomide—skin cancer	0.0015	0.00515	CcSEcCtD
Lisuride—Asthenia—Imiquimod—skin cancer	0.00146	0.00504	CcSEcCtD
Lisuride—Confusional state—Bleomycin—skin cancer	0.00146	0.00503	CcSEcCtD
Lisuride—Infection—Bleomycin—skin cancer	0.00144	0.00495	CcSEcCtD
Lisuride—HTR2A—connective tissue—skin cancer	0.00139	0.00834	CbGeAlD
Lisuride—Anorexia—Bleomycin—skin cancer	0.00138	0.00475	CcSEcCtD
Lisuride—HTR1A—head—skin cancer	0.00138	0.00825	CbGeAlD
Lisuride—Dizziness—Imiquimod—skin cancer	0.00135	0.00464	CcSEcCtD
Lisuride—ADRA2A—mammalian vulva—skin cancer	0.00135	0.00808	CbGeAlD
Lisuride—Vertigo—Temozolomide—skin cancer	0.00135	0.00463	CcSEcCtD
Lisuride—Infection—Dactinomycin—skin cancer	0.00134	0.00462	CcSEcCtD
Lisuride—Palpitations—Temozolomide—skin cancer	0.00132	0.00455	CcSEcCtD
Lisuride—HTR2A—epithelium—skin cancer	0.00132	0.00792	CbGeAlD
Lisuride—Cough—Temozolomide—skin cancer	0.00131	0.0045	CcSEcCtD
Lisuride—Weight increased—Docetaxel—skin cancer	0.0013	0.00448	CcSEcCtD
Lisuride—Vomiting—Imiquimod—skin cancer	0.0013	0.00446	CcSEcCtD
Lisuride—Weight decreased—Docetaxel—skin cancer	0.00129	0.00445	CcSEcCtD
Lisuride—Dyspnoea—Bleomycin—skin cancer	0.00129	0.00445	CcSEcCtD
Lisuride—Anorexia—Dactinomycin—skin cancer	0.00129	0.00443	CcSEcCtD
Lisuride—Headache—Imiquimod—skin cancer	0.00128	0.0044	CcSEcCtD
Lisuride—Anxiety—Temozolomide—skin cancer	0.00127	0.00437	CcSEcCtD
Lisuride—Decreased appetite—Bleomycin—skin cancer	0.00126	0.00433	CcSEcCtD
Lisuride—Dry mouth—Temozolomide—skin cancer	0.00125	0.00429	CcSEcCtD
Lisuride—DRD2—head—skin cancer	0.00124	0.00745	CbGeAlD
Lisuride—Confusional state—Temozolomide—skin cancer	0.00123	0.00424	CcSEcCtD
Lisuride—Infection—Temozolomide—skin cancer	0.00122	0.00418	CcSEcCtD
Lisuride—ADRA2C—head—skin cancer	0.00121	0.00725	CbGeAlD
Lisuride—Nervous system disorder—Temozolomide—skin cancer	0.0012	0.00413	CcSEcCtD
Lisuride—Feeling abnormal—Bleomycin—skin cancer	0.0012	0.00411	CcSEcCtD
Lisuride—Hyperhidrosis—Temozolomide—skin cancer	0.00118	0.00407	CcSEcCtD
Lisuride—Decreased appetite—Dactinomycin—skin cancer	0.00118	0.00404	CcSEcCtD
Lisuride—Fatigue—Dactinomycin—skin cancer	0.00117	0.00401	CcSEcCtD
Lisuride—Anorexia—Temozolomide—skin cancer	0.00117	0.00401	CcSEcCtD
Lisuride—ADRA2A—female reproductive system—skin cancer	0.00116	0.00692	CbGeAlD
Lisuride—Confusional state—Fluorouracil—skin cancer	0.00114	0.00391	CcSEcCtD
Lisuride—Oedema peripheral—Docetaxel—skin cancer	0.00113	0.00388	CcSEcCtD
Lisuride—Infection—Fluorouracil—skin cancer	0.00112	0.00385	CcSEcCtD
Lisuride—Feeling abnormal—Dactinomycin—skin cancer	0.00111	0.00383	CcSEcCtD
Lisuride—Insomnia—Temozolomide—skin cancer	0.00111	0.0038	CcSEcCtD
Lisuride—Nervous system disorder—Fluorouracil—skin cancer	0.00111	0.0038	CcSEcCtD
Lisuride—Tachycardia—Fluorouracil—skin cancer	0.0011	0.00378	CcSEcCtD
Lisuride—Dyspnoea—Temozolomide—skin cancer	0.00109	0.00375	CcSEcCtD
Lisuride—Somnolence—Temozolomide—skin cancer	0.00109	0.00374	CcSEcCtD
Lisuride—HTR2B—lymph node—skin cancer	0.00108	0.00645	CbGeAlD
Lisuride—Anorexia—Fluorouracil—skin cancer	0.00107	0.00369	CcSEcCtD
Lisuride—Decreased appetite—Temozolomide—skin cancer	0.00106	0.00366	CcSEcCtD
Lisuride—Cardiac disorder—Docetaxel—skin cancer	0.00106	0.00365	CcSEcCtD
Lisuride—Gastrointestinal disorder—Temozolomide—skin cancer	0.00106	0.00363	CcSEcCtD
Lisuride—Fatigue—Temozolomide—skin cancer	0.00105	0.00363	CcSEcCtD
Lisuride—Constipation—Temozolomide—skin cancer	0.00105	0.0036	CcSEcCtD
Lisuride—Asthenia—Bleomycin—skin cancer	0.00104	0.00358	CcSEcCtD
Lisuride—Angiopathy—Docetaxel—skin cancer	0.00104	0.00357	CcSEcCtD
Lisuride—Immune system disorder—Docetaxel—skin cancer	0.00103	0.00356	CcSEcCtD
Lisuride—Mediastinal disorder—Docetaxel—skin cancer	0.00103	0.00355	CcSEcCtD
Lisuride—Insomnia—Fluorouracil—skin cancer	0.00102	0.00351	CcSEcCtD
Lisuride—Feeling abnormal—Temozolomide—skin cancer	0.00101	0.00347	CcSEcCtD
Lisuride—Dyspnoea—Fluorouracil—skin cancer	0.00101	0.00346	CcSEcCtD
Lisuride—Mental disorder—Docetaxel—skin cancer	0.001	0.00345	CcSEcCtD
Lisuride—Somnolence—Fluorouracil—skin cancer	0.001	0.00345	CcSEcCtD
Lisuride—Malnutrition—Docetaxel—skin cancer	0.000997	0.00343	CcSEcCtD
Lisuride—HTR2A—female reproductive system—skin cancer	0.000983	0.00588	CbGeAlD
Lisuride—Decreased appetite—Fluorouracil—skin cancer	0.00098	0.00337	CcSEcCtD
Lisuride—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000973	0.00335	CcSEcCtD
Lisuride—Asthenia—Dactinomycin—skin cancer	0.000971	0.00334	CcSEcCtD
Lisuride—ADRA2A—head—skin cancer	0.000965	0.00578	CbGeAlD
Lisuride—Feeling abnormal—Fluorouracil—skin cancer	0.000929	0.00319	CcSEcCtD
Lisuride—Vomiting—Bleomycin—skin cancer	0.000922	0.00317	CcSEcCtD
Lisuride—CYP3A4—female reproductive system—skin cancer	0.00091	0.00545	CbGeAlD
Lisuride—CYP2D6—female reproductive system—skin cancer	0.000895	0.00536	CbGeAlD
Lisuride—Syncope—Docetaxel—skin cancer	0.000894	0.00307	CcSEcCtD
Lisuride—Palpitations—Docetaxel—skin cancer	0.000881	0.00303	CcSEcCtD
Lisuride—Asthenia—Temozolomide—skin cancer	0.000878	0.00302	CcSEcCtD
Lisuride—Cough—Docetaxel—skin cancer	0.00087	0.00299	CcSEcCtD
Lisuride—Vomiting—Dactinomycin—skin cancer	0.00086	0.00296	CcSEcCtD
Lisuride—ADRA2C—lymph node—skin cancer	0.000847	0.00507	CbGeAlD
Lisuride—Dry mouth—Docetaxel—skin cancer	0.00083	0.00285	CcSEcCtD
Lisuride—HTR2A—head—skin cancer	0.000821	0.00492	CbGeAlD
Lisuride—Confusional state—Docetaxel—skin cancer	0.00082	0.00282	CcSEcCtD
Lisuride—Dizziness—Temozolomide—skin cancer	0.000809	0.00278	CcSEcCtD
Lisuride—Infection—Docetaxel—skin cancer	0.000808	0.00278	CcSEcCtD
Lisuride—Nervous system disorder—Docetaxel—skin cancer	0.000798	0.00274	CcSEcCtD
Lisuride—Tachycardia—Docetaxel—skin cancer	0.000794	0.00273	CcSEcCtD
Lisuride—Vomiting—Temozolomide—skin cancer	0.000778	0.00267	CcSEcCtD
Lisuride—Anorexia—Docetaxel—skin cancer	0.000776	0.00267	CcSEcCtD
Lisuride—Headache—Temozolomide—skin cancer	0.000767	0.00264	CcSEcCtD
Lisuride—CYP2D6—head—skin cancer	0.000748	0.00448	CbGeAlD
Lisuride—Dizziness—Fluorouracil—skin cancer	0.000745	0.00256	CcSEcCtD
Lisuride—Insomnia—Docetaxel—skin cancer	0.000736	0.00253	CcSEcCtD
Lisuride—Dyspnoea—Docetaxel—skin cancer	0.000725	0.00249	CcSEcCtD
Lisuride—Somnolence—Docetaxel—skin cancer	0.000723	0.00249	CcSEcCtD
Lisuride—Vomiting—Fluorouracil—skin cancer	0.000717	0.00246	CcSEcCtD
Lisuride—Decreased appetite—Docetaxel—skin cancer	0.000707	0.00243	CcSEcCtD
Lisuride—Headache—Fluorouracil—skin cancer	0.000706	0.00243	CcSEcCtD
Lisuride—Gastrointestinal disorder—Docetaxel—skin cancer	0.000702	0.00242	CcSEcCtD
Lisuride—Fatigue—Docetaxel—skin cancer	0.000702	0.00241	CcSEcCtD
Lisuride—Constipation—Docetaxel—skin cancer	0.000696	0.00239	CcSEcCtD
Lisuride—ADRA2A—lymph node—skin cancer	0.000676	0.00405	CbGeAlD
Lisuride—Feeling abnormal—Docetaxel—skin cancer	0.000671	0.00231	CcSEcCtD
Lisuride—Asthenia—Docetaxel—skin cancer	0.000584	0.00201	CcSEcCtD
Lisuride—Dizziness—Docetaxel—skin cancer	0.000538	0.00185	CcSEcCtD
Lisuride—Vomiting—Docetaxel—skin cancer	0.000517	0.00178	CcSEcCtD
Lisuride—Headache—Docetaxel—skin cancer	0.00051	0.00175	CcSEcCtD
Lisuride—DRD1—Signaling Pathways—FOXO4—skin cancer	4.67e-05	0.000496	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—RASA1—skin cancer	4.66e-05	0.000495	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—SMO—skin cancer	4.64e-05	0.000493	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTCH1—skin cancer	4.64e-05	0.000493	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—ENO2—skin cancer	4.63e-05	0.000492	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—FOXO4—skin cancer	4.6e-05	0.000489	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—FOXO4—skin cancer	4.6e-05	0.000489	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PTGER4—skin cancer	4.54e-05	0.000483	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTGER4—skin cancer	4.52e-05	0.00048	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTCH1—skin cancer	4.52e-05	0.00048	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—SMO—skin cancer	4.52e-05	0.00048	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTCH1—skin cancer	4.44e-05	0.000472	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—SMO—skin cancer	4.44e-05	0.000472	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CSPG4—skin cancer	4.44e-05	0.000471	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTGER4—skin cancer	4.4e-05	0.000467	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTGER4—skin cancer	4.33e-05	0.00046	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SHH—skin cancer	4.32e-05	0.000459	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—RASA1—skin cancer	4.3e-05	0.000456	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SHH—skin cancer	4.25e-05	0.000452	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—RASA1—skin cancer	4.23e-05	0.000449	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—FOXO4—skin cancer	4.2e-05	0.000446	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—FOXO4—skin cancer	4.16e-05	0.000442	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SMO—skin cancer	4.1e-05	0.000435	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTCH1—skin cancer	4.1e-05	0.000435	CbGpPWpGaD
Lisuride—ADRA2B—Hemostasis—NRAS—skin cancer	4.08e-05	0.000433	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTCH1—skin cancer	4.03e-05	0.000428	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SMO—skin cancer	4.03e-05	0.000428	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—FOXO4—skin cancer	4.01e-05	0.000426	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—FOXO4—skin cancer	3.99e-05	0.000424	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTGER4—skin cancer	3.99e-05	0.000424	CbGpPWpGaD
Lisuride—DRD5—Signaling by GPCR—NRAS—skin cancer	3.95e-05	0.00042	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTGER4—skin cancer	3.92e-05	0.000417	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—FOXO4—skin cancer	3.88e-05	0.000413	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SHH—skin cancer	3.87e-05	0.000411	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—RASA1—skin cancer	3.84e-05	0.000409	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—FOXO4—skin cancer	3.82e-05	0.000406	CbGpPWpGaD
Lisuride—ADRA2C—Hemostasis—NRAS—skin cancer	3.81e-05	0.000405	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—BRAF—skin cancer	3.72e-05	0.000395	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTCH1—skin cancer	3.67e-05	0.00039	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SMO—skin cancer	3.67e-05	0.00039	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PLIN2—skin cancer	3.6e-05	0.000382	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TERT—skin cancer	3.59e-05	0.000382	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTGER4—skin cancer	3.57e-05	0.000379	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—FOXO4—skin cancer	3.52e-05	0.000374	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TERT—skin cancer	3.52e-05	0.000374	CbGpPWpGaD
Lisuride—ADRA2B—Hemostasis—KRAS—skin cancer	3.51e-05	0.000373	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—FOXO4—skin cancer	3.47e-05	0.000368	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TERT—skin cancer	3.46e-05	0.000368	CbGpPWpGaD
Lisuride—DRD5—Signaling by GPCR—KRAS—skin cancer	3.4e-05	0.000361	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—ERCC2—skin cancer	3.31e-05	0.000352	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TERT—skin cancer	3.31e-05	0.000351	CbGpPWpGaD
Lisuride—ADRA2C—Hemostasis—KRAS—skin cancer	3.28e-05	0.000348	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—FOXO4—skin cancer	3.15e-05	0.000335	CbGpPWpGaD
Lisuride—ADRA2B—Hemostasis—TP53—skin cancer	3.12e-05	0.000331	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TERT—skin cancer	3.12e-05	0.000331	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—NRAS—skin cancer	3.09e-05	0.000329	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TERT—skin cancer	3.08e-05	0.000327	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TERT—skin cancer	3.08e-05	0.000327	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—NRAS—skin cancer	3.03e-05	0.000322	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ENO2—skin cancer	3.02e-05	0.00032	CbGpPWpGaD
Lisuride—ADRA2B—Hemostasis—HRAS—skin cancer	2.98e-05	0.000317	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—NRAS—skin cancer	2.96e-05	0.000315	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—NRAS—skin cancer	2.92e-05	0.00031	CbGpPWpGaD
Lisuride—ADRA2C—Hemostasis—TP53—skin cancer	2.91e-05	0.000309	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CSPG4—skin cancer	2.9e-05	0.000308	CbGpPWpGaD
Lisuride—DRD5—Signaling by GPCR—HRAS—skin cancer	2.89e-05	0.000307	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—BRAF—skin cancer	2.85e-05	0.000302	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TERT—skin cancer	2.8e-05	0.000298	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—BRAF—skin cancer	2.79e-05	0.000296	CbGpPWpGaD
Lisuride—ADRA2C—Hemostasis—HRAS—skin cancer	2.79e-05	0.000296	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—NRAS—skin cancer	2.78e-05	0.000296	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TERT—skin cancer	2.78e-05	0.000295	CbGpPWpGaD
Lisuride—DRD5—Signaling by GPCR—IL6—skin cancer	2.77e-05	0.000294	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—BRAF—skin cancer	2.74e-05	0.000291	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—ERCC2—skin cancer	2.69e-05	0.000286	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TERT—skin cancer	2.68e-05	0.000285	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TERT—skin cancer	2.67e-05	0.000283	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—KRAS—skin cancer	2.66e-05	0.000283	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—NRAS—skin cancer	2.63e-05	0.000279	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—BRAF—skin cancer	2.62e-05	0.000278	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—KRAS—skin cancer	2.61e-05	0.000277	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TERT—skin cancer	2.59e-05	0.000276	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—NRAS—skin cancer	2.59e-05	0.000275	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—NRAS—skin cancer	2.59e-05	0.000275	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TERT—skin cancer	2.55e-05	0.000271	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—KRAS—skin cancer	2.55e-05	0.000271	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—KRAS—skin cancer	2.51e-05	0.000267	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—BRAF—skin cancer	2.47e-05	0.000262	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—BRAF—skin cancer	2.44e-05	0.000259	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—BRAF—skin cancer	2.44e-05	0.000259	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—KRAS—skin cancer	2.4e-05	0.000255	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—TP53—skin cancer	2.37e-05	0.000251	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—NRAS—skin cancer	2.36e-05	0.000251	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TERT—skin cancer	2.35e-05	0.00025	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—NRAS—skin cancer	2.34e-05	0.000249	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—NRAS—skin cancer	2.33e-05	0.000248	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TERT—skin cancer	2.32e-05	0.000246	CbGpPWpGaD
Lisuride—ADRA2A—Hemostasis—HRAS—skin cancer	2.26e-05	0.00024	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—KRAS—skin cancer	2.26e-05	0.00024	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—NRAS—skin cancer	2.26e-05	0.00024	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—NRAS—skin cancer	2.25e-05	0.000239	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—KRAS—skin cancer	2.23e-05	0.000237	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—KRAS—skin cancer	2.23e-05	0.000237	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—BRAF—skin cancer	2.22e-05	0.000236	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—HRAS—skin cancer	2.21e-05	0.000235	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—BRAF—skin cancer	2.2e-05	0.000234	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—NRAS—skin cancer	2.19e-05	0.000232	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—HRAS—skin cancer	2.17e-05	0.00023	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—NRAS—skin cancer	2.15e-05	0.000229	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—HRAS—skin cancer	2.13e-05	0.000227	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—BRAF—skin cancer	2.12e-05	0.000226	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—IL6—skin cancer	2.12e-05	0.000225	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—BRAF—skin cancer	2.11e-05	0.000224	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TERT—skin cancer	2.11e-05	0.000224	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—IL6—skin cancer	2.08e-05	0.000221	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—BRAF—skin cancer	2.05e-05	0.000218	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—IL6—skin cancer	2.04e-05	0.000217	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—HRAS—skin cancer	2.04e-05	0.000216	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—KRAS—skin cancer	2.03e-05	0.000216	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—BRAF—skin cancer	2.02e-05	0.000215	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—KRAS—skin cancer	2.01e-05	0.000214	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—KRAS—skin cancer	2.01e-05	0.000214	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PTGS2—skin cancer	1.98e-05	0.000211	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—NRAS—skin cancer	1.98e-05	0.000211	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ENO2—skin cancer	1.97e-05	0.000209	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.95e-05	0.000207	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—IL6—skin cancer	1.95e-05	0.000207	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—KRAS—skin cancer	1.94e-05	0.000207	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.93e-05	0.000205	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—HRAS—skin cancer	1.92e-05	0.000204	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—HRAS—skin cancer	1.9e-05	0.000201	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—HRAS—skin cancer	1.9e-05	0.000201	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—KRAS—skin cancer	1.88e-05	0.0002	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—BRAF—skin cancer	1.86e-05	0.000198	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—KRAS—skin cancer	1.85e-05	0.000197	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—IL6—skin cancer	1.84e-05	0.000195	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—BRAF—skin cancer	1.83e-05	0.000195	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—IL6—skin cancer	1.81e-05	0.000193	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—IL6—skin cancer	1.81e-05	0.000193	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—NRAS—skin cancer	1.79e-05	0.00019	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—TP53—skin cancer	1.79e-05	0.00019	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—NRAS—skin cancer	1.77e-05	0.000189	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ERCC2—skin cancer	1.75e-05	0.000186	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—NRAS—skin cancer	1.75e-05	0.000186	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—HRAS—skin cancer	1.73e-05	0.000184	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—NRAS—skin cancer	1.72e-05	0.000183	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—HRAS—skin cancer	1.71e-05	0.000182	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—HRAS—skin cancer	1.71e-05	0.000181	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—KRAS—skin cancer	1.71e-05	0.000181	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—KRAS—skin cancer	1.68e-05	0.000178	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—BRAF—skin cancer	1.67e-05	0.000177	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—IL6—skin cancer	1.65e-05	0.000176	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—HRAS—skin cancer	1.65e-05	0.000176	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—NRAS—skin cancer	1.65e-05	0.000175	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—HRAS—skin cancer	1.64e-05	0.000175	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—IL6—skin cancer	1.64e-05	0.000174	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—IL6—skin cancer	1.63e-05	0.000174	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTGS2—skin cancer	1.61e-05	0.000171	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—HRAS—skin cancer	1.6e-05	0.00017	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—IL6—skin cancer	1.58e-05	0.000168	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—HRAS—skin cancer	1.57e-05	0.000167	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—IL6—skin cancer	1.57e-05	0.000167	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—NRAS—skin cancer	1.55e-05	0.000165	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—KRAS—skin cancer	1.54e-05	0.000164	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—NRAS—skin cancer	1.53e-05	0.000163	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—NRAS—skin cancer	1.53e-05	0.000163	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—IL6—skin cancer	1.53e-05	0.000163	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—KRAS—skin cancer	1.53e-05	0.000162	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—KRAS—skin cancer	1.51e-05	0.00016	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—IL6—skin cancer	1.51e-05	0.00016	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—KRAS—skin cancer	1.48e-05	0.000158	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—HRAS—skin cancer	1.45e-05	0.000154	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—HRAS—skin cancer	1.43e-05	0.000152	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—skin cancer	1.42e-05	0.00015	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—NRAS—skin cancer	1.39e-05	0.000148	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—skin cancer	1.39e-05	0.000148	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—NRAS—skin cancer	1.38e-05	0.000147	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—skin cancer	1.37e-05	0.000145	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—skin cancer	1.37e-05	0.000145	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—skin cancer	1.34e-05	0.000142	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—skin cancer	1.34e-05	0.000142	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—NRAS—skin cancer	1.33e-05	0.000142	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NRAS—skin cancer	1.33e-05	0.000141	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—skin cancer	1.32e-05	0.00014	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—skin cancer	1.32e-05	0.00014	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—skin cancer	1.32e-05	0.00014	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—skin cancer	1.31e-05	0.000139	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—skin cancer	1.3e-05	0.000138	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NRAS—skin cancer	1.29e-05	0.000137	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—skin cancer	1.28e-05	0.000136	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NRAS—skin cancer	1.27e-05	0.000135	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—skin cancer	1.26e-05	0.000134	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—skin cancer	1.26e-05	0.000134	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—skin cancer	1.25e-05	0.000133	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—skin cancer	1.24e-05	0.000132	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—skin cancer	1.23e-05	0.00013	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—skin cancer	1.21e-05	0.000128	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—skin cancer	1.2e-05	0.000128	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—skin cancer	1.2e-05	0.000128	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—skin cancer	1.19e-05	0.000126	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—skin cancer	1.19e-05	0.000126	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NRAS—skin cancer	1.17e-05	0.000124	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—skin cancer	1.17e-05	0.000124	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—skin cancer	1.17e-05	0.000124	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NRAS—skin cancer	1.15e-05	0.000122	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—skin cancer	1.15e-05	0.000122	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—skin cancer	1.15e-05	0.000122	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ERCC2—skin cancer	1.15e-05	0.000122	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—skin cancer	1.14e-05	0.000121	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—skin cancer	1.13e-05	0.000121	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—skin cancer	1.12e-05	0.000119	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—skin cancer	1.12e-05	0.000119	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—skin cancer	1.11e-05	0.000118	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—skin cancer	1.09e-05	0.000116	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—skin cancer	1.09e-05	0.000115	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—skin cancer	1.07e-05	0.000114	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—skin cancer	1.07e-05	0.000114	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—skin cancer	1.07e-05	0.000113	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—skin cancer	1.06e-05	0.000112	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—skin cancer	1.05e-05	0.000112	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NRAS—skin cancer	1.05e-05	0.000111	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—skin cancer	1.02e-05	0.000108	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—skin cancer	1.02e-05	0.000108	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—skin cancer	1.02e-05	0.000108	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—skin cancer	1.01e-05	0.000107	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—skin cancer	1.01e-05	0.000107	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—skin cancer	9.92e-06	0.000105	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—skin cancer	9.87e-06	0.000105	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—skin cancer	9.77e-06	0.000104	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—skin cancer	9.76e-06	0.000104	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—skin cancer	9.72e-06	0.000103	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—skin cancer	9.71e-06	0.000103	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—skin cancer	9.68e-06	0.000103	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—skin cancer	9.44e-06	0.0001	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—skin cancer	9.34e-06	9.92e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—skin cancer	9.29e-06	9.88e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—skin cancer	9.29e-06	9.87e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—skin cancer	9.04e-06	9.6e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—skin cancer	9.02e-06	9.59e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—skin cancer	8.96e-06	9.52e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—skin cancer	8.9e-06	9.45e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—skin cancer	8.82e-06	9.37e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—skin cancer	8.57e-06	9.1e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—skin cancer	8.43e-06	8.96e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—skin cancer	8.2e-06	8.71e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—skin cancer	8.07e-06	8.57e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—skin cancer	8.02e-06	8.52e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—skin cancer	7.67e-06	8.15e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—skin cancer	7.34e-06	7.8e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—skin cancer	6.87e-06	7.3e-05	CbGpPWpGaD
